ANIP Ani Pharmaceuticals PE ratio, current and historical analysis
The current PE ratio of ANIP can't be determined, as the TTM EPS of -$0.55 is negative. The most recent PE ratio recorded for Ani Pharmaceuticals was 53.97 in June 2024.
ANIP PE ratio history
Over the last ten years, the average PE ratio of Ani Pharmaceuticals has been 452.72. Over the past ten years, ANIP's PE ratio was at its highest in the Jun 2018 quarter at 6,680, with a price of $66.8 and an EPS of $0.01. The Sep 2015 quarter recorded the bottom point at 13.21, with a price of $39.51 and an EPS of $2.99.
Ani Pharmaceuticals PE ratio by year
Maximum annual increase: 429.36% in 2016
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 64.12 | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | N/A | N/A |
| 2019 | 120.92 | 251.82% |
| 2018 | 34.37 | N/A |
| 2017 | N/A | N/A |
| 2016 | 178.29 | 429.36% |
| 2015 | 33.68 | 55.85% |
| 2014 | 21.61 | N/A |
ANIP average PE ratio chart
ANIP PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVS Novartis AG | 11.44 | $197.39B |
| RPRX Royalty Pharma plc | 11.73 | $17.76B |
| JAZZ Jazz Pharmaceuticals plc | 16.33 | $7.36B |
| CAH Cardinal Health Inc | 24.78 | $31.07B |
| PFE Pfizer Inc | 34.74 | $149.61B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $24.94B |
| CLDX Celldex Therapeutics Inc | N/A | $1.61B |
| ANIP Ani Pharmaceuticals Inc | N/A | $1.22B |
Frequently asked questions
What is Ani Pharmaceuticals's PE ratio?
The current price to earnings ratio of ANIP can't be calculated, as its EPS of -$0.55 is negative.
What is the highest PE ratio for ANIP?
Over the last ten years, the quarterly PE ratio reached a historic high of 6,680 in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.